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tim.cheetham@nuth.nhs.ukSummaryAim: Differentiating familial cranial diabetes insipidus (CDI) from primary polydipsia can be difficult. We report the
diagnostic utility of genetic testing as a means of confirming or excluding this diagnosis.
Patient and methods: The index case presented at 3 months with polydipsia. He was diagnosed with familial CDI based on a
positive family history combined with what was considered to be suspicious symptomatology and biochemistry. He was
treated with desmopressin (DDAVP) but re-presented at 5 months of age with hyponatraemia and the DDAVP was stopped.
Gene sequencing of the vasopressin gene in father and his offspring was undertaken to establish the underlying
molecular defect.
Results: Both father and daughter were found to have the pathogenic mutation c.242TOC (p.Leu81Pro) in exon 2 of the
AVP gene consistent with a diagnosis of familial diabetes insipidus. The index case did not have the pathogenic mutation and
the family could be reassured that he would not require intervention with DDAVP.
Conclusions: Gene sequencing of AVP gene can have a valuable role in predicting whether or not a child is at risk of
developing CDI in future. This can help to prevent family uncertainty and unnecessary treatment with its associated risks.Learning points:
† Differentiating patients with familial cranial diabetes insipidus from those with primary polydipsia is not always
straightforward.
† Molecular genetic analysis of the vasopressin gene is a valuable way of confirming or refuting a diagnosis of familial
CDI in difficult cases and is a valuable way of identifying individuals who will develop CDI in later childhood. This
information can be of great value to families.Background
Familial cranial diabetes insipidus (FCDI) is a rare
inherited disorder that may have an autosomal dominant
inheritance pattern. Polyuria and polydipsia typically
develop in childhood due to a progressive decline in AVPsecretion and selective degeneration of AVP-producing
neurons (1). Differentiating evolving cranial diabetes
from the more common cause of excessive fluid intake,
primary polydipsia, is not always straightforward. In ourhttp://www.edmcasereports.com
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phase of cranial diabetes insipidus (CDI) when AVP
secretion is declining. Here, we highlight the diagnostic
utility of AVP gene sequencing in the context of a child
with suspected autosomal dominant cranial diabetes
insipidus who became hyponatraemic while on desmo-
pressin (DDAVP) medication.Case presentation
The index case was thought to be drinking excessively
by his parents at 3 months of age. Father had been
diagnosed with CDI in adolescence and was on regular
DDAVP therapy under the care of the adult endocrine
team. The child’s older female half-sibling had been
diagnosed with CDI at 8 years of age and was stable on
DDAVP therapy.
The index case was assessed in clinic and the com-
bination of a positive family history, suspected polyuria
despite loose stools and poor feeding combinedwith a urine
osmolality of 53 mOsm/kg at the time of a serum sodium
of 140 mmol/l and serum osmolality of 284 mOsm/kg was
thought to be indicative of the child-developingCDI like his
father. He was therefore commenced on nasal DDAVP in a
dose of 5 mg b.d. The DDAVP dose was subsequently
increased up to 15 mg b.d. because of ongoing concerns
about an excessive thirst and urine output.
The infant was admitted to hospital at 5months of age
with a history of poor feeding, diarrhoea and vomiting.
Investigations at the time of his admission revealed a
sodium of 120 mmol/l in the presence of a low serum
creatinine (Table 1). The admitting team initially won-
dered about the possibility of inter-current infection but
the diagnosis was revised to include one of water
intoxication and the DDAVP was stopped. In light of the
fact that the biochemistry at the time of DDAVP initiation
had not been diagnostic of CDI, it was felt appropriate
to conduct further investigations including a water
deprivation test.Table 1 Resolution of hyponatraemia following cessation of DDA
Day and time
Serum sodium
(mmol/l)
Serum osmolality
(mOsm/kg)
Day 1 22.00 120
Day 2 06.00 125 257
Day 2 14.00 127
Day 3 08.00 127
Day 5 11.00 136 283
Day 5 13.00 136 282
http://www.edmcasereports.comForty-eight hours after admission, the infant’s sodium
level had risen to 127 mmol/l (Table 1). Five days after
admission, he underwent an eight-and-a-half-hour fast,
at the end of which his sodium level was 136 mmol/l and
his urine osmolality level was 563 mOsm/l. He had not
received any DDAVP formore than 4 days. The patient was
discharged with advice regarding offering water inter-
mittently in addition to milk and solid feeds.Investigation
Genetic analysis
In discussion with the family, it was decided to investigate
the father with a view to establishing the underlying
molecular defect in the vasopressin gene.We agreed that it
would then be appropriate to establish whether his
offspring were affected by the same molecular defect.
PCR of the three AVP coding exons and flanking
intronic sequences was performed separately using the
primers mentioned in Table 2. Primers were tagged with
universal primers UniSeq. The reaction containedw150 ng
genomic DNA, 1U Immolase Taq (Bioline Reagents Ltd,
London, UK), 20 pmol of each primer, 200 mM dNTPs,
1.5 mM MgCl2, 2! ImmoBuffer (Bioline) and 15% DMSO
in a total volume of 20 ml.
The PCR conditions consisted of an initial denaturing
step at 95 8C for 5 min followed by 32 cycles of denaturation
(1 min at 95 8C), annealing (1 min at 60 8C for exon1, 1 min
at 65 8C for exons 2 and 3) and extension (1 min at 72 8C)
with a final extension step at 72 8C for 10 min.DNA sequencing
Amplified targets were purified using AmPure (Agencourt,
Beverly, MA, USA) and directly sequenced in the forward
and reverse directions using ABI Big Dye Terminator v3.1
cycle sequencing kit (Applied Biosystems). Sequencing
products were purified using CleanSDefault (Agencourt)VP.
Serum creatinine
(mmol/l)
Urine osmolality
(mOsm/kg)
Urine sodium
(mmol/l)
!20 62 !10
!20 63 !10
17 72
25
!20 563
22
2
Table 2 Primers used in vasopressin gene analysis.
Exon Forward sequence Reverse sequence
1 GAACACCTGCGGACATAAATAG CTAAAGGCTACCACCACCCATG
2 AGCCCTGGACCCCAGCATC CAGCCCCCACCCCGCCGCA
3 GTTTGCTGCAACGACGGTGC GAGGCCGTGCATTGGCGGAG
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(Applied Biosystems). Sequence traces were analysed
using Mutation Surveyor v3.97 (Soft Genetics, State
College, PA, USA).Treatment
The result of genetic testing was available within 4 weeks.
Both father and daughter were found to have the
pathogenic mutation c.242TOC (p.Leu81Pro) in exon 2
of the AVP gene consistent with a diagnosis of familial
diabetes insipidus. This change had been reported
previously in another kindred (2).
Genetic testing of the index case showed that he did
not have the pathogenic mutation and hence was not at
significant risk of developing CDI.Outcome and follow-up
The child was discharged without further follow-up.Discussion
This case highlights the valuable role of genetic testing in
the assessment and management of children with
suspected CDI. A child with a family history of autosomal
dominant CDI and who is thought to be polyuric with a
low urine osmolality at the time of illness will have a
relatively high likelihood of being similarly affected.
Parental concerns about evolving CDI may also have
some bearing on the assessment and management of a
clinical scenario like this.
However, it is important to highlight the fact that the
child’s biochemistry was not diagnostic of CDI and the
development of hyponatraemia reflected water intoxi-
cation following DDAVP medication. This case therefore
highlights the importance of using robust clinical,
biochemical and potentially molecular genetic criteria
before commencing DDAVP therapy.
Familial CDI is rare, accounting for about 5% of all
cases. The clinical expression of familial autosomal
dominant disorder does not usually occur in infancy but
instead at around 5–10 years (3).http://www.edmcasereports.comAssessment of the child with suspected DImay involve
water deprivation testing, although this test is unpopular
with children, parents and health professionals and does
not necessarily provide a definitive diagnosis.
Genetic analysis of patients where there is a relevant
family history can therefore be undertaken in early life
following discussion with the family (4). This can be used
to identify children who are likely to develop CDI and will
help parents and health professionals to monitor (or not
monitor) potential symptoms and signs as the child
matures (5) (6). In a cost-conscious health service, it
should also be stressed that the cost of genetic analysis
(100 pounds for the index case and 70 pounds for each
additional family member) is much cheaper than the cost
of a water deprivation test (300–400 pounds).
In conclusion, we have shown that genetic analysis of
the AVP gene can have a valuable role in identifying
whether or not a child with a family history of CDI will
develop or is at risk of developing CDI in future.Patient’s perspective
Due to themisdiagnosis, I nearly lost my son. Obviously, if
a genetic test had been carried out prior to this, this would
not have happened and I would not have been in this
situation. Luckily, he is now well with no problems.Declaration of interest
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